1. A vehicle driveline comprising:
a first driveline component;
a second driveline component; and
a torque transmitting device having:
an input portion having a shaft with a thread formed thereon, the input portion being coupled for rotation with a rotatable power transmitting member of the first driveline component;
an output portion coupled for rotation with a rotatable power transmitting member of the second driveline component, the output portion having a first case member, a second case member and an overload spring, the first case member being axially slidably but non-rotatably mounted on the second case member, the overload spring biasing the first and second case members toward one another;
first and second cone clutch surfaces mounted on the thread on the shaft of the input portion; and
first and second mating cone clutch surfaces received between the first case member and the second case member, at least one of the first and second mating cone clutch surfaces being axially slidably but non-rotatably coupled to the second case member.
2. The vehicle driveline of claim 1, wherein a stop member is formed on the shaft, the stop member inhibiting movement of at least one of the first and second cone clutch surfaces in a predetermined axial direction relative to the shaft beyond a predetermined location.
3. The vehicle driveling of claim 2, wherein the first and second cone clutch surfaces are integrally formed on a nut.
4. The vehicle driveline of claim 1, wherein the first case member includes an annular flange that abuts a structure onto which at least one of the first and second mating cone clutch surfaces is formed.
5. The vehicle driveline of claim 1, wherein the torque transmitting device further includes third and fourth cone clutch surfaces and third and fourth mating cone clutch surfaces, the third and fourth cone clutch surfaces being mounted on the shaft of the input portion, the third and fourth mating cone clutch surfaces received between the first case member and the second case member and being non-rotatably coupled to the second case member.
6. The vehicle driveline of claim 5, wherein the third and fourth cone clutch surfaces are non-movably coupled to the shaft.
7. The vehicle driveline of claim 6, wherein the torque transmitting device further includes a drag spring that engages a structure that is coupled to the first and second cone clutch surfaces.
8. The vehicle driveline of claim 7, wherein the overload spring comprises a plurality of spring elements that are disposed about the second case member.
9. The vehicle driveline of claim 8, wherein the first case member includes a housing and a plurality of pins, the pins being fixedly coupled to the housing, each of the spring elements being received over a corresponding one of the pins.
10. The vehicle driveline of claim 9, wherein each of the pins includes a pin flange and a guide portion, wherein each of the spring elements is received between a corresponding one of the pin flanges and a flange member formed on the second case member, and wherein each guide portion is slidably received in guide bore formed in the second case member.
11. A method for transmitting torque through a vehicle driveline comprising:
providing a torque transmitting device having a threaded shaft, a first and second cone clutch members, a housing, and first and second cone clutch members, the first and second cone clutch members being threadably received on the threaded shaft, the housing including a first housing member and a second housing member, the first housing member being axially slidably but non-rotatably coupled to the second housing member, a portion of the first and second mating cone clutch members being axially slidably but non-rotatably coupled to the second housing member;
biasing the first housing member toward the second housing member;
rotating the threaded shaft relative to the first cone clutch member in a first rotational direction to drive the first cone clutch member against the first mating cone clutch member; and
continuing rotation of the threaded shaft relative to the first cone clutch member in the first rotational direction to axially move the threaded shaft to cause the second cone clutch member to engage the second mating cone clutch member.
12. The method of claim 11, further comprising:
continuing rotation of the threaded shaft relative to the first cone clutch member in the first rotational direction to abut the first cone clutch against a rotational stop that is coupled to the threaded shaft; and
driving the first housing member away from the second housing member to axially separate the portion of the first and second mating cone clutch members from the remaining portion of the first and second mating cone clutch members.
13. A torque transmitting device comprising:
an input portion having a shaft with a thread formed thereon, the input portion being adapted to be coupled for rotation with a rotatable power transmitting member of a first driveline component;
an output portion adapted to be coupled for rotation with a rotatable power transmitting member of a second driveline component, the output portion having a first case member, a second case member and an overload spring, the first case member being axially slidably but non-rotatably mounted on the second case member, the overload spring biasing the first and second case members toward one another;
first and second cone clutch surfaces mounted on the thread on the shaft of the input portion; and
first and second mating cone clutch surfaces received between the first case member and the second case member, at least one of the first and second mating cone clutch surfaces being axially slidably but non-rotatably coupled to the second case member.
14. The torque transmitting device of claim 13, wherein a stop member is formed on the shaft, the stop member inhibiting movement of at least one of the first and second cone clutch surfaces in a predetermined axial direction relative to the shaft beyond a predetermined location.
15. The torque transmitting device of claim 14, wherein the first and second cone clutch surfaces are integrally formed on a nut.
16. The torque transmitting device of claim 13, wherein the first case member includes an annular flange that abuts a structure onto which at least one of the first and second mating cone clutch surfaces is formed.
17. The torque transmitting device of claim 13, wherein the torque transmitting device further includes third and fourth cone clutch surfaces and third and fourth mating cone clutch surfaces, the third and fourth cone clutch surfaces being mounted on the shaft of the input portion, the third and fourth mating cone clutch surfaces received between the first case member and the second case member and being non-rotatably coupled to the second case member.
18. The torque transmitting device of claim 17, wherein the third and fourth cone clutch surfaces are non-movably coupled to the shaft.
19. The torque transmitting device of claim 18, wherein the torque transmitting device further includes a drag spring that engages a structure that is coupled to the first and second cone clutch surfaces.
20. The torque transmitting device of claim 19, wherein the overload spring comprises a plurality of spring elements that are disposed about the second case member.
21. The torque transmitting device of claim 20, wherein the first case member includes a housing and a plurality of pins, the pins being fixedly coupled to the housing, each of the spring elements being received over a corresponding one of the pins.
22. The torque transmitting device of claim 21, wherein each of the pins includes a pin flange and a guide portion, wherein each of the spring elements is received between a corresponding one of the pin flanges and a flange member formed on the second case member, and wherein each guide portion is slidably received in guide bore formed in the second case member.
The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.
1. A bioactive ingredient comprising:
an isolated bioactive fraction derived from cell juice of fresh biomass of a feverfew (Tanacetum parthenium) plant, wherein said bioactive fraction is either free of or substantially free of \u03b1-unsaturated \u03b3-lactones, said \u03b1-unsaturated \u03b3-lactones comprising parthenolide, and wherein said bioactive fraction has anti-inflammatory and antioxidant activity.
2. The bioactive ingredient according to claim 1, wherein the bioactive fraction is free of parthenolide.
3. The bioactive ingredient according to claim 1, wherein the bioactive fraction is substantially free of parthenolide.
4. The bioactive ingredient according to claim 3, wherein the bioactive fraction has a parthenolide concentration of equal to or less than about 0.01 weight percent.
5. The bioactive ingredient according to claim 1, wherein the bioactive fraction has an anti-inflammatory activity ranging from an IC50 value of between about 0.01 percent (volume by volume) and about 2.0 percent (volume by volume), wherein said IC50 value represents the concentration of bioactive ingredient required to decrease the speed of elastase enzymatic reaction by 50 percent.
6. The bioactive ingredient according to claim 1, wherein the bioactive fraction has an antioxidant activity ranging from an IC50 value of between about 0.007 percent (volume by volume) and about 1.0 percent (volume by volume), wherein said IC50 value represents the concentration of bioactive ingredient required to decrease the speed of cytochrome c reduction by 50 percent.
7. The bioactive ingredient according to claim 1 further comprising a stabilizing agent.
8. A method for isolating a bioactive fraction that is derived from cell juice of fresh biomass of a feverfew (Tanacetum parthenium) plant and that is substantially free of \u03b1-unsaturated \u03b3-lactones, said method comprising:
providing fresh biomass of a feverfew (Tanacetum parthenium) plant;
processing the fresh biomass under conditions effective to yield a cell juice supernatant and a membrane fraction;
treating the cell juice supernatant under conditions effective to yield a first cell juice serum supernatant and a cytoplasm fraction precipitate; and
isolating the cytoplasm fraction precipitate, wherein said cytoplasm fraction precipitate is a bioactive fraction that is substantially free of \u03b1-unsaturated \u03b3-lactones, wherein said \u03b1-unsaturated \u03b3-lactones comprise parthenolide.
9. The method according to claim 8, wherein the step of processing the fresh biomass comprises:
separating the fresh biomass into a cell juice component and a fiber enriched material;
clarifying the cell juice component to yield a clarified cell juice component; and
separating the clarified cell juice component into the cell juice supernatant and the membrane fraction.
10. The method according to claim 8 further comprising:
clarifying the first cell juice serum supernatant under conditions effective to yield a second cell juice serum supernatant;
mixing a stabilizing agent with the second cell juice serum supernatant under conditions effective to yield a stabilized cell juice serum fraction,
wherein said stabilized cell juice serum fraction is a bioactive fraction that is substantially free of \u03b1-unsaturated \u03b3-lactones, said \u03b1-unsaturated \u03b3-lactones comprising parthenolide.
11. The method according to claim 10 further comprising:
concentrating the stabilized cell juice serum fraction under conditions effective to yield a concentrated cell juice serum supernatant.
12. The method according to claim 11 further comprising:
mixing a stabilizing agent with the concentrated cell juice serum supernatant under conditions effective to yield a stabilized concentrated cell juice serum fraction,
wherein said stabilized concentrated cell juice serum fraction is a bioactive fraction that is free of \u03b1-unsaturated \u03b3-lactones, said \u03b1-unsaturated \u03b3-lactones comprising parthenolide.
13. A bioactive ingredient comprising the cytoplasm fraction precipitate produced according to the method of claim 8, wherein said cytoplasm fraction precipitate is a bioactive fraction that is substantially free of \u03b1-unsaturated \u03b3-lactones, said \u03b1-unsaturated \u03b3-lactones comprising parthenolide.
14. A bioactive ingredient comprising the stabilized cell juice serum fraction produced according to claim 10, wherein said stabilized cell juice serum fraction is a bioactive fraction that is substantially free of \u03b1-unsaturated \u03b3-lactones, said \u03b1-unsaturated \u03b3-lactones comprising parthenolide.
15. The bioactive ingredient according to claim 14, wherein said stabilized cell juice serum fraction has an anti-inflammatory activity ranging from an IC50 value of between about 0.01 percent (volume by volume) and about 2.0 percent (volume by volume), wherein said IC50 value represents the concentration of bioactive ingredient required to decrease the speed of elastase enzymatic reaction by 50 percent.
16. The bioactive ingredient according to claim 14, wherein said stabilized cell juice serum fraction has an antioxidant activity ranging from an IC50 value of between about 0.007 percent (volume by volume) and about 1.0 percent (volume by volume), wherein said IC50 value represents the concentration of bioactive ingredient required to decrease the speed of cytochrome c reduction by 50 percent.
17. A bioactive ingredient comprising the stabilized concentrated cell juice serum fraction produced according to claim 12, wherein said stabilized concentrated cell juice serum fraction is a bioactive fraction that is free of \u03b1-unsaturated \u03b3-lactones, said \u03b1-unsaturated \u03b3-lactones comprising parthenolide.
18. The bioactive ingredient according to claim 17, wherein said stabilized concentrated cell juice serum fraction has an anti-inflammatory activity ranging from an IC50 value of between about 0.01 percent (volume by volume) and about 2.0 percent (volume by volume), wherein said IC50 value represents the concentration of bioactive ingredient required to decrease the speed of elastase enzymatic reaction by 50 percent.
19. The bioactive ingredient according to claim 17, wherein said stabilized concentrated cell juice serum fraction has an antioxidant activity ranging from an IC50 value of between about 0.007 percent (volume by volume) and about 1.0 percent (volume by volume), wherein said IC50 value represents the concentration of bioactive ingredient required to decrease the speed of cytochrome c reduction by 50 percent.
20. A bioactive composition comprising:
a mixture of one or more isolated bioactive fractions derived from cell juice of fresh biomass of a feverfew (Tanacetum parthenium) plant, wherein the bioactive fractions are each either free of or substantially free of \u03b1-unsaturated \u03b3-lactones, said \u03b1-unsaturated \u03b3-lactones comprising parthenolide, and wherein the bioactive fractions have anti-inflammatory and antioxidant activity.
21. The bioactive composition according to claim 20, wherein the one or more isolated bioactive fractions comprise bioactive fractions selected from the group consisting of Supernatant I, Supernatant II, Precipitate II (Bioactive Ingredient A), Final Supernatant, Bioactive Ingredient B, Concentrated Final Supernatant, and Bioactive Ingredient C.
22. The bioactive composition according to claim 1 further comprising a stabilizing agent.